Stock Comparison

JNJ vs RMD

Johnson & Johnson vs Resmed Inc

The Verdict

JNJ takes this one.

Winner

JNJ

Johnson & Johnson

1.0

out of 10

Distressed

RMD

Resmed Inc

0.1

out of 10

Distressed

Head-to-Head

$557.1B

Market Cap

$28.4B

26.5

P/E Ratio

18.7

21.8%

Profit Margin

27.4%

26.3%

Return on Equity

24.4%

0.6

Debt-to-Equity

0.1

Conservative

Overall Risk

Moderate

1.0

DVR Score

0.1

The Deep Dive

JNJ1.0/10

Johnson & Johnson (JNJ) continues to demonstrate robust financial performance, with Q1 2026 results exceeding consensus on both revenue and adjusted EPS, reflecting nearly 10% YoY revenue growth. Its diversified healthcare portfolio provides significant market leadership and a wide economic moat, indicating stability and consistent profitability. However, its massive market capitalization of $555....

Full JNJ Analysis

RMD0.1/10

ResMed Inc. (RMD) continues to demonstrate robust performance as a global leader in sleep apnea and respiratory care. Its Q3 FY2026 results showed healthy 10.8% YoY revenue growth, EPS beat ($2.86 vs $2.79 consensus), and gross margin expansion to 62.8%. These are strong indicators of a well-managed, profitable company in an established healthcare sector. However, this analysis specifically target...

Full RMD Analysis

Want More Comparisons?

Run any stock through our deep value analyzer.

Analyze Any Stock →

Not Financial Advice

This comparison is for educational purposes only. We are not financial advisors. Always do your own research and consult a qualified advisor before investing.